We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-4.25%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$87.1M
AUM Growth
-$39.1M
(-31%)
Cap. Flow
-$42.6M
Cap. Flow
% of AUM
-48.9%
Top 10 Holdings %
Top 10 Hldgs %
44.48%
Holding
450
New
86
Increased
61
Reduced
79
Closed
202
Top Buys
| 1 |
Constellation Brands
STZ
|
+$3.18M |
| 2 |
JPMorgan Chase
JPM
|
+$3.16M |
| 3 |
General Mills
GIS
|
+$2.29M |
| 4 |
Gilead Sciences
GILD
|
+$2.29M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Top Sells
| 1 |
Procter & Gamble
PG
|
+$4.04M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$3.96M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$2.56M |
| 4 |
iShares Biotechnology ETF
IBB
|
+$2.03M |
| 5 |
Humana
HUM
|
+$1.77M |
Sector Composition
| 1 | Healthcare | 44.7% |
| 2 | Consumer Staples | 14.06% |
| 3 | Consumer Discretionary | 4.38% |
| 4 | Financials | 4.11% |
| 5 | Communication Services | 3.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Regeneron Pharmaceuticals
REGN
$70.9B
| $9.79M | 11.24% |
26,665
-323
| -1% | -$123K |
|
2
Abbott
ABT
$175B
| $5.68M | 6.53% |
147,970
-3,665
| -2% | -$145K |
|
|
3
JPMorgan Chase
JPM
$907B
| $3.58M | 4.11% |
+41,500
| New | +$3.16M |
|
4
Akebia Therapeutics
AKBA
$359M
| $3.52M | 4.05% |
338,640
-27,478
| -8% | -$237K |
|
|
5
Gilead Sciences
GILD
$167B
| $3.38M | 3.88% |
47,227
+30,806
| +188% | +$2.29M |
|
|
6
General Mills
GIS
$20.3B
| $3.37M | 3.86% |
54,477
+36,971
| +211% | +$2.29M |
|
|
7
Constellation Brands
STZ
$22.7B
| $3.07M | 3.52% |
+20,000
| New | +$3.18M |
|
|
8
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
| $2.18M | 2.5% |
101,100
+26,800
| +36% | +$10.2M |
|
|
GWPH
9
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $2.17M | 2.49% |
129,200
-1,900
| -1% | -$229K |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $2M | 2.3% |
+16,335
| New | +$2M |
|
|
OTIC
11
DELISTED
Otonomy, Inc.
OTIC
| $1.88M | 2.16% |
118,473
-20,612
| -15% | -$345K |
|
|
POT
12
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.72M | 1.98% |
95,080
| – | – |
|
|
TWX
13
DELISTED
Time Warner Inc
TWX
| $1.68M | 1.93% |
+17,386
| New | +$1.55M |
|
|
PNRA
14
DELISTED
Panera Bread Co
PNRA
| $1.28M | 1.47% |
+6,243
| New | +$1.26M |
|
15
AbbVie
ABBV
$450B
| $1.25M | 1.43% |
+19,886
| New | +$1.21M |
|
16
Kimberly-Clark
KMB
$36B
| $1.16M | 1.33% |
+10,150
| New | +$1.18M |
|
|
MNK
17
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $1.11M | 1.27% |
22,200
+17,196
| +344% | +$1.01M |
|
18
Rocket Pharmaceuticals
RCKT
$376M
| $1.1M | 1.27% |
45,293
+6,077
| +15% | +$173K |
|
|
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
| $1.07M | 1.23% |
28,116
+2,363
| +9% | +$112K |
|
20
Target
TGT
$63.4B
| $1.05M | 1.2% |
+14,502
| New | +$1.05M |
|
21
CALL
Exelixis
EXEL
$14.1B
| $1.02M | 1.17% |
171,900
-64,400
| -27% | -$929K |
|
|
SE
22
DELISTED
Spectra Energy Corp Wi
SE
| $992K | 1.14% |
+24,150
| New | +$1M |
|
23
Clorox
CLX
$11.6B
| $944K | 1.08% |
+7,862
| New | +$927K |
|
|
CMRX
24
DELISTED
Chimerix, Inc.
CMRX
| $944K | 1.08% |
205,266
| – | – |
|
25
Biogen
BIIB
$30.4B
| $905K | 1.04% |
+3,191
| New | +$946K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q4 2016 Portfolio in Review
As of Q4 2016, FT Options held 450 positions worth $87.1M, down 31% from $126M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
FT Options withdrew a net $42.6M in Q4 2016, closing 202 positions and reducing 79 holdings. Its most notable exit was Procter & Gamble, an estimated $4.04M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 40% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, FT Options opened a new position in Constellation Brands worth $3.07M.
- FT Options's largest Q4 2016 buy was Constellation Brands: 20,000 shares worth $3.07M.
- FT Options added most to General Mills in Q4 2016, an estimated $2.29M increase.
- FT Options's biggest Q4 2016 reduction was Monsanto Co, cutting an estimated $1.06M.
- FT Options fully exited Procter & Gamble in Q4 2016, selling an estimated $4.04M.
- FT Options's ten largest holdings make up 44% of its $87.1M portfolio in Q4 2016.
- FT Options opened 86 new positions and closed 202 in Q4 2016.
- FT Options's portfolio value fell 31% quarter-over-quarter to $87.1M.
Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.